Visionary pioneers, Biosceptre’s researchers are leading the way with nfP2X7-targeted oncology therapeutics that have the potential to benefit millions of cancer patients across the world.
We made a very exciting advance in cancer research, the discovery of nfP2X7 – a new oncology target shown to be present on a broad range of cancers types. We are currently driving several nfP2X7-targeted CAR T-cell and antibody therapies towards clinical stage that, we believe, could provide treatment options for a great number of patients whose cancer has resisted other therapies.
Headquartered in the UK, Biosceptre is undertaking therapeutic development efforts in Cambridge, England and Sydney, Australia and has secured a significant global IP portfolio.
With Nobel prize-winning science leadership, globally-renowned researchers and collaboration with major research institutes, Biosceptre is committed to a future of targeted oncology where nfP2X7 technology forms the cornerstone.